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CLINICAL INVESTIGATION

Effect of Inflammatory Bowel Disease–Related Characteristics
and Treatment Interventions on Cardiovascular
Disease Incidence
Sudeep D. Thapa, MD, Hiba Hadid, MD, Jason Schairer, MD, Waseem Imam, DO and
Syed-Mohammed Jafri, MD

Abstract: Background: An association between inﬂammatory bowel
disease (IBD) and cardiovascular diseases has been shown in multiple
studies. However, little is known about the effect of IBD-related
characteristics on cardiovascular events. Methods: The authors
conducted a retrospective, nested case-control study of IBD patients
who presented to the institution from 2000 to 2004, allowing for
a 10-year follow-up period. One hundred eleven patients who
developed cardiovascular events (cases) and 222 patients who did
not develop cardiovascular events (cases) were included in the study
after matching for Framingham cardiovascular risk score (2008).
Relationships between predictor variables and cardiovascular outcome were assessed by conditional logistic regression. Results: The
cases and controls were similar in age, gender, smoking and
cholesterol level. There was no difference in disease subtype
(ulcerative colitis or Crohn’s disease). On conditional logistic regression, thiopurine treatment (odds ratio [OR]: 0.42, 95% conﬁdence
interval [CI]: 0.19–0.87; P 5 0.02) was associated with decreased
cardiovascular events and tumor necrosis factor alpha antagonist use
(OR: 2.63, 95% CI: 1.49–4.63; P 5 0.001) was associated with
increased cardiovascular events. Although not statistically signiﬁcant,
disease-related surgery (OR: 0.57, 95% CI: 0.32–1.02; P 5 0.06) was
associated with decreased cardiovascular events and disease-related
hospitalization (OR: 1.58, 95% CI: 0.96–2.57; P 5 0.07) was associated with increased incidence of cardiovascular disorders.
Conclusions: The authors observed decreased incidence of cardiovascular diseases in patients with IBD who were treated with
thiopurines and increased incidence of cardiovascular outcomes
among patients treated with tumor necrosis factor alpha antagonist.
Key Indexing Terms: Inﬂammatory bowel disease; Crohn’s disease;
Ulcerative colitis; Coronary artery disease; Thiopurine; Biological
agents. [Am J Med Sci 2015;350(3):175–180.]

I

nﬂammatory bowel disease (IBD) is a chronic inﬂammatory
disorder associated with intestinal and extraintestinal manifestations. Cardiovascular disorders have increased incidence
among patients suffering from chronic inﬂammatory diseases.1 Among IBD patients, studies have been contradictory
with some studies showing increased cardiovascular events,1
whereas others have not shown increased risk.2 Although the
pathogenic link between IBD and cardiovascular disorders is
not well known, inﬂammation is considered to be the general
mechanism of pathogenesis in both disorders. In addition,
inﬂammatory markers that are increased in patients with
From the Departments of Internal Medicine (SDT, HH, WI) and Gastroenterology (JS, SMJ), Henry Ford Hospital, Madison Heights, Michigan.
Submitted February 19, 2015; accepted in revised form June 12, 2015.
The authors have no ﬁnancial or other conﬂicts of interest to disclose.
Correspondence: Sudeep D. Thapa, MD, Internal Medicine, Henry
Ford Hospital, 2799 West Grand Boulevard, Detroit, MI 48071 (E-mail:
dr.sdthapa@gmail.com).

The American Journal of the Medical Sciences



IBD have been associated with cardiovascular diseases3 and
multiple studies have shown IBD patients to be at increased
risk of developing cardiovascular events.1
Furthermore, vascular alterations are common in IBD
patients. Early arterial wall alterations have been observed in
IBD patients, marked by increased carotid artery intima-media
thickness which is a marker of atherogenesis.4 Even children
with IBD have early endothelial dysfunction based on increased
intima-media thickness and reduced ﬂow-mediated dilatation.5
On the contrary, some studies in the past have not shown
increased cardiovascular disease risk among IBD patients.2,6
Therefore, the current evidence is not sufﬁcient to deﬁnitively
conclude that IBD patients are at increased risk of developing
cardiovascular disorders.6
However, increased inﬂammation among IBD patients has
been shown to increase the risk of cardiovascular diseases. A
nationwide cohort study from Denmark showed increased risk of
cardiovascular death during active IBD.7 Another retrospective
study by Yarur et al8 showed increased risk of coronary artery
disease in IBD patients compared with the general population
despite having lower burden of traditional risk factors.
Despite the increasing knowledge that inﬂammation in
IBD is associated with increased risk of cardiovascular
diseases, the disease-related characteristics and the effect of
anti-inﬂammatory medications used in IBD on cardiovascular
disease incidence are poorly understood. Furthermore, most
studies so far have focused on acute coronary events rather
than the long-term evolution of cardiovascular diseases
in IBD.
The aim of the present study was to explore the effect of
disease-related characteristics, including disease activity, severity and treatment, on cardiovascular disease incidence among
IBD patients over a 10-year follow-up period.

METHODS
This study was approved by the Henry Ford Hospital
Institutional Review Board.
Subject Identification and Data Collection
The authors used Henry Ford Hospital medical record
databases that contain medical and demographic information
for patients evaluated at Henry Ford Health System. These
databases were used to identify patients who presented with
IBD from January 1, 2000, to December 31, 2004, to allow for
a 10-year follow-up period. International Classiﬁcation of
Diseases, Ninth Revision, codes 555.x and 556.x were used to
identify patients with IBD.
Cases and Controls
The inclusion criteria included the following: (1) age at
presentation between 30 and 74 years, (2) histological evidence
of IBD and (3) follow-up data available for greater than 5 years.
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Exclusion criterion was medical history of cardiovascular or
cerebrovascular disease. Records for a cohort of 2,525 IBD
cases who had been evaluated in the IBD clinic at Henry Ford
Hospital from 2000 to 2004 were reviewed. A total of 1,188
patients were excluded because they did not meet the inclusion
criteria or had history of cardiovascular or cerebrovascular
disease. One thousand three hundred thirty-seven patients met
the study criteria. There were 111 patients who subsequently
developed cardiovascular diseases.
Framingham risk score (2008) was used to measure the
baseline general cardiovascular disease risk for all patients
included in the study. Patients between the age of 30 and 74
years were selected because the Framingham risk score (2008)
applies to this age group. The Framingham risk score (2008) is
a validated risk score that is used to calculate the risk of
developing general cardiovascular disorders over a period of 10
years.9 The score is based on age, gender, smoking status, total
cholesterol level, high-density lipoprotein (HDL) level and
systolic blood pressure.
A total of 111 cases with cardiovascular disorders were
identiﬁed and matched for Framingham risk score with 2
controls for each case. Cases were deﬁned as patients who
developed incidental cardiovascular diseases, including coronary artery disease, heart failure, stroke or peripheral artery
disease on objective testing. Some patients developed multiple
cardiovascular conditions. Cases were identiﬁed by reviewing
medical records for objective evidence of cardiovascular
disease (ejection fraction less than 40% on echocardiography,
computed tomography scan head or magnetic resonance
imaging brain with evidence of stroke, carotid artery Doppler
ultrasound with atherosclerotic narrowing, ankle-brachial index
suggestive of peripheral artery disease, computed tomography
angiography with coronary calciﬁcation, ﬁxed wall motion
abnormality on echocardiography, cardiac stress test suggestive
of coronary artery disease). Controls were chosen from IBD
patients in the cohort who did not develop cardiovascular
diseases. Physician notes from the hospital and from outside
health-care facilities were also reviewed when available for
history of cardiovascular disease. None of the control patients
had any history of cardiovascular disorders. Cases and controls
were propensity matched for Framingham risk score (2008) by
“nearest neighbor method.”
Variables and Outcomes
Information regarding age at presentation, gender and race
(white, black or other) was extracted. Lifetime history of smoking
more than 1 pack year or current smoker was recorded.
Colonoscopy results on extent of anatomical disease involvement
were also collected. Histopathology results for intestinal tissue
obtained during colonoscopy were reviewed for active inﬂammation during the follow-up period. The total cholesterol and
HDL and low-density lipoprotein levels were collected during the
initial clinic visit. Patient records were reviewed for blood
pressure at initial presentation. All the recorded blood pressures,
glycated hemoglobin levels and cholesterol levels during the
follow-up period were also reviewed for the development of
diabetes, hypertension and/or hyperlipidemia during the followup period. These data were used to calculate the Framingham risk
score (2008) for cardiovascular risk prediction.
Disease characteristic was divided as follows: ulcerative
colitis (UC) patients were divided into panulcerative colitis and
non-panulcerative colitis. Crohn’s disease (CD) patients were
divided into inﬂammatory disease or ﬁstulizing/stricturing disease. Age at onset of disease was also abstracted. Colonoscopy
reports were reviewed for histological evidence of active
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inﬂammation during the follow-up period, and data regarding
need for disease-related hospitalization were also reviewed from
medical records for identifying patients with active inﬂammation
during the follow-up period. Peak erythrocyte sedimentation rate
(ESR) was also abstracted as a marker of inﬂammation.
Data regarding the use of IBD-related medications,
including 5-aminosalicylates, corticosteroids, thiopurines (6mercaptopurine and azathioprine) and antitumor necrosis factor
agents (inﬂiximab, adalimumab and certolizumab pegol), were
collected. Only medications used before the development of
cardiovascular events were included.
The primary outcome of this study was a composite of
cardiovascular events, including coronary artery disease, heart
failure, peripheral vascular disease and stroke. Composite outcomes are often used in studies with cardiovascular endpoint.
Statistical Analyses
R software, version 3.0.1, for all statistical analyses was
used. Continuous variables were summarized using medians
and interquartile range (IQR), and categorical variables were
expressed as proportions. Categorical variables were analyzed
using the x2 test and ﬁsher’s exact test, and continuous variables were analyzed using t test or Wilcoxon signed rank test for
parametric and nonparametric data, respectively. Framingham
risk score was used as a continuous variable. Cases and controls
were matched for the Framingham risk score (2008) using the
nearest neighbor method.
Variables with a P value less than 0.1 on univariate
conditional logistic regression analysis were included in the
multivariate conditional logistic regression model.
Secondary analysis comparing patients who developed
hard cardiovascular endpoints (myocardial infarction, stroke
and heart failure) with the control population was also
conducted. Predictor variables were identiﬁed using univariate
logistic regression. Variables with P value less than 0.1 in the
univariate model were included in the multivariate logistic
regression model.
The effect was expressed as odds ratio (OR) with 95%
conﬁdence interval (CI), along with P values.

RESULTS
The median age for the cases was 56 years (IQR, 47.5–
64.5), and the median age of the controls was 54 years (IQR, 46–
62). Data involving 3,410 patient years were reviewed for ﬁnal
analysis. The cases consisted of 64.86% Caucasian and 53.15%
were men. The controls consisted of 58.5% Caucasians and
46.85% were men. The mean systolic blood pressures on initial
presentation were 133.1 mm Hg for cases and 134 mm Hg for
controls. The median Framingham risk score for general cardiovascular disease risk (2008) for cases was 14.54 (IQR, 6.66–
24.58) and for controls was 13.41 (IQR, 6.62–20.44). The median
follow-up period for cases was 9.53 years (IQR, 9.19–10.22). The
median follow-up for controls was 9.82 years (IQR, 8.9–12.19)
(Table 1). Of the cohort, 111 patients developed cardiovascular
events. There were 67 cases of coronary artery disease, 23 cases of
stroke, 25 cases of heart failure and 31 cases of peripheral vascular
disease. Some patients had multiple cardiovascular events.
Cases and controls were matched for Framingham risk
score (2008) for cardiovascular risk. Matching was done using
the nearest neighbor method. There was no difference in the
median Framingham score between the cases and controls
(14.54 versus 13.41, P 5 0.27).
The median age at IBD diagnosis for cases was 45 years
(IQR, 32.5–53.5) and for controls was 44 years (IQR, 31.25–52).
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TABLE 1. Demographic and clinical characteristics of cases and controls
Demographics
Cases (n 5 111)
Age, median (IQR), yr
Male
HDL, median (IQR), mg/dL
Smoking
Total cholesterol, median (IQR), mg/dL
Hypertension
Diabetes mellitus
Framingham score (IQR)
CD
Stricturing CD
UC
Pancolonic UC
IBD duration (IQR)
Age at onset (IQR)
ESR (IQR)
Hospitalization
Hospitalization frequency
No hospitalization
1–3 hospitalization
.3 hospitalization
Active inﬂammation on biopsy
Disease-related surgery
5-ASA
Steroids
Thiopurines
TNF antagonist

56
59
51
44
198
63
13
14.54
46
11
66
36
9
45
45
69
42
68
1
82
22
83
47
11
36

(47.5–64.5)
(53.15%)
(41–59)
(39.64%)
(167.5–226)
(56.76%)
(11.71%)
(6.66–24.58)
(41.44%)
(9.9%)
(59.46%)
(32.43%)
(5–17.5)
(32.5–53.5)
(23–59.5)
(62.16%)
(37.84%)
(61.26%)
(0.9%)
(73.87%)
(19.82%)
(74.78%)
(42.34%)
(9.91%)
(32.43%)

Controls (n 5 222)
54
52
53
67
199.5
106
31
13.41
81
22
141
73
9
44
40
115
107
111
4
147
68
170
112
48
41

P

(46–62)
(46.85%)
(43–64.75)
(30.18%)
(174–231.8)
(47.75%)
(13.96%)
(6.62–20.44)
(36.49%)
(9.9%)
(63.51%)
(32.88%)
(4–18)
(31.25–52)
(24–53)
(51.8%)

0.15
0.97
0.22
0.49
0.37
0.15
0.69
0.27
0.45
0.83
0.55
0.84
0.43
0.68
0.12
0.09

(48.19%)
(50%)
(1.8%)
(66.22%)
(30.63%)
(76.58%)
(50.45%)
(20.62%)
(18.47%)

0.14

0.19
0.05
0.82
0.2
0.01
0.007

CD, Crohn’s disease; UC, ulcerative colitis.

Proportion of patients with pancolitis and ﬁstulizing/stricturing
CD was similar between the cases and controls (Table 1). The
disease activity during the follow-up period was evaluated
using the need for disease-related hospitalization, peak ESR
level and the presence of active inﬂammation on biopsy samples obtained during colonoscopy. The median ESR level for
cases was 45 mm/hr (IQR, 23–59.5) and 40 mm/hr (IQR, 24–
53) for controls. The need for disease-related hospitalization
and the presence of active inﬂammation on biopsy were also
higher among the cases compared with the controls (Table 1).
There was no difference between cases and controls in
the use of sulfa medications or steroids (Table 1). Tumor necrosis factor (TNF) alpha antagonist use was more common among
the cases compared with controls (36 versus 41, P 5 0.004).
Thiopurine use was less common among patients with cardiovascular events (11 versus 48, P 5 0.01). Some patients were
on multiple medications.
On univariate conditional logistic regression, diseaserelated hospitalization (OR: 1.59, 95% CI: 0.92–2.77; P 5
0.06), active inﬂammation on biopsy during the follow-up
period (OR: 1.19, 95% CI: 1.05–3.97; P 5 0.04) and TNFalpha antagonist use (OR: 2.6, 95% CI: 1.37–4.95; P 5
0.004) were associated with increased risk of cardiovascular
events. Disease-related surgery (OR: 0.55, 95% CI: 0.27–1.1;
P 5 0.09) and thiopurine use (OR: 0.45, 95% CI: 0.19–1.06;
P 5 0.07) were associated with decreased risk of cardiovascular events. Variables with P value less than 0.1 were included
in the multivariate regression model. On multivariate conditional logistic regression, thiopurine use was associated with

decreased odds of developing cardiovascular diseases (OR:
0.39, 95% CI: 0.19–0.83; P 5 0.01) and TNF-alpha antagonist
use was associated with increased odds of developing cardiovascular diseases (OR: 2.59, 95% CI: 1.49–4.51; P 5 0.001).
Although not statistically signiﬁcant, history of disease-related
surgery was associated with decreased cardiovascular events
(OR: 0.56, 95% CI: 0.32–1.01; P 5 0.053) and need for
disease-related hospitalization was associated with increased
risk of cardiovascular events (OR: 1.59, 95% CI: 0.97–2.58;
P 5 0.06) (Table 2).
On secondary analysis, patients who developed cardiovascular events (myocardial infarction, stroke and heart failure)
were compared with the control group. On univariate logistic
regression, HDL, hypertension, Framingham risk score, steroid
use, thiopurine and TNF-alpha antagonist use were associated
with cardiovascular events at a predeﬁned P value ,0.1
(Table 3). On multivariate logistic regression, HDL was slightly
protective against cardiovascular events (OR: 0.98, 95% CI:
0.96–0.99; P 5 0.03), thiopurine use was associated with
decreased cardiovascular events (OR: 0.28, 95% CI: 0.08–
0.73; P 5 0.047) and TNF-alpha antagonist use was associated
with increased cardiovascular events (OR: 3.42, 95% CI: 1.74–
6.75; P 5 0.0004).

DISCUSSION
Development of atherosclerotic lesions is inﬂuenced by
major inﬂammatory factors that encompass components of both
the innate and the acquired immune systems. There is
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TABLE 2. Conditional logistic regression for combined cardiovascular outcome
Multivariate logistic regression
Characteristics
Age
Gender (male vs. female)
HDL
Smoking
Total cholesterol
Hypertension
Diabetes mellitus
Framingham score
IBD subtype
CD
UC
Stricturing CD
Pancolonic UC
Age at onset
IBD duration
ESR
Hospitalization
Hospitalization frequency (0 vs. 1–3 vs. more than 3 admissions)
Active inﬂammation on biopsy
Surgery
5-ASA
Steroids
Thiopurines
TNF antagonist

Univariate logistic regression
OR (95% CI)

P

1.01
1.03
0.99
1.2
0.99
1.26
0.83
1.19

(0.98–1.04)
(0.58–1.81)
(0.98–1.01)
(0.67–2.17)
(0.99–1.01)
(0.69–2.28)
(0.33–2.09)
(0.83–1.72)

0.59
0.93
0.46
0.54
0.99
0.45
0.69
0.33

1.06
0.98
0.91
1.13
0.99
1.01
1.01
1.59
1.19
2.04
0.55
0.98
0.65
0.45
2.6

(0.61–1.87)
(0.56–1.71)
(0.59–1.38)
(0.69–1.93)
(0.97–1.01)
(0.99–1.04)
(0.99–1.02)
(0.92–2.77)
(0.62–2.29)
(1.05–3.97)
(0.27–1.1)
(0.53–1.81)
(0.37–1.12)
(0.19–1.06)
(1.37–4.95)

0.83
0.94
0.65
0.66
0.51
0.24
0.17
0.09
0.6
0.04
0.09
0.94
0.12
0.07
0.004

OR (95% CI)

P

1.59 (0.97–2.58)

0.06

1.53 (0.89–2.6)
0.56 (0.32–1.01)

0.12
0.053

0.39 (0.19–0.83)
2.59 (1.49–4.51)

0.01
0.001

CD, Crohn’s disease; UC, ulcerative colitis.

substantial evidence supporting the role of metabolic disturbances combined with dysregulated inﬂammation as the
mechanism of atherosclerosis in coronary arteries.10 There is
also evidence that patients with IBD are at increased risk of
cardiovascular diseases1 despite having lower burden of traditional risk factors.8 However, the disease-related characteristics
and the effect of medications on cardiovascular system remain
poorly understood. In this study, increased cardiovascular outcomes among IBD patients with increased disease activity as
observed by TNF-alpha antagonist use and disease-related hospitalization were observed. Paradoxically, decreased cardiovascular disease incidence was observed among patients treated with
thiopurines and those requiring disease-related surgery. Age at
onset of IBD and disease characteristics (pancolitis versus nonpancolitis for UC and stricturing/ﬁstulizing versus inﬂammatory
for CD) were also used as surrogate disease severity parameters.
These variables are known to predict severity of disease in IBD.11
Furthermore, the presence of histological evidence of inﬂammation during the follow-up period, need for disease-related hospitalization and peak ESR levels were used as surrogate markers of
disease activity. There was no difference between cases and controls in peak ESR levels and disease characteristics (pancolitis
versus non-pancolitis for UC and stricturing/ﬁstulizing versus
inﬂammatory for CD) (Table 1).
Despite the increased understanding of various immunological pathways, the exact mechanisms that link cardiovascular disorders and IBD remain unknown. However, there are
several immunological dysfunctions that are common in both
IBD and cardiovascular disorders. Inﬂammatory cytokines,
including interleukin 1, interleukin 6 and TNF, are involved
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in the pathogenesis of IBD12; these cytokines are also known to
play a role in the development of cardiovascular disorders.13 In
fact, c-reactive protein, which is a marker of inﬂammation and
found in higher concentrations in patients with active IBD, has
also been shown to be a modiﬁable cardiovascular risk factor.14
Toll-like receptors (TLR) and autophagy are recently discovered immunological mechanisms, which have been found to be
dysfunctional in both IBD and cardiovascular disorders. TLRs
are expressed on a large number of immune cells and play an
essential role in the activation of the innate immune response to
microbial pathogens. Dysfunction in the interaction between
TLRs plays a role in the pathogenesis of both coronary artery
disease and IBD.15 Autophagy is another mechanism that can
explain the association between cardiovascular events and CD.
Both cardiovascular disorders and CD have defects in autophagy.16 Although these similarities in immunological disorders
do not mean causation, it does point to common pathogenic
links between cardiovascular disorders and IBD.
In this study, the authors found increased odds of
developing cardiovascular diseases in patients treated with
TNF-alpha antagonists. This is most likely because TNF-alpha
antagonist use is a marker of IBD severity and activity. IBD
patients with the most severe disease activity, which is not well
controlled with other medications, are treated with TNF-alpha
antagonists. This ﬁnding lends further support that patients with
severe IBD are at increased risk of developing cardiovascular
disorders. However, there have been reports of cardiovascular
events in patients using TNF-alpha antagonist,17,18 and heart failure in particular has been strongly linked to these medications.19
However, there have also been reports of improvement in
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TABLE 3. Logistic regression analysis for combined cardiovascular events (heart failure, myocardial infarction and stroke)
Multivariate logistic regression
Univariate logistic regression
OR (95% CI)
P
OR (95% CI)
P
Characteristics
Age
Gender (female vs. male)
HDL
Smoking
Total cholesterol
Hypertension
Diabetes mellitus
Framingham score
IBD subtype
CD
UC
Stricturing CD
Pancolonic UC
Age at onset
IBD duration
ESR
Hospitalization
Hospitalization frequency (0 vs. 1–3 vs.
more than 3 admissions)
Active inﬂammation on biopsy
Surgery
5-ASA
Steroids
Thiopurines
Biological agents

1
0.6
0.98
1.38
0.99
2.31
1.03
1.02

(0.98–1.03)
(0.32–1.1)
(0.96–0.99)
(0.76–2.51)
(0.99–1.003)
(1.26–4.37)
(0.42–2.28)
(0.99–1.04)

0.77
0.11
0.053
0.29
0.31
0.008
0.95
0.06

1.04
1.03
0.96
1.32
0.99
1.01
1.01
1.15
1.07

(0.56–1.9)
(0.57–1.93)
(0.61–1.48)
(0.71–2.41)
(0.98–1.02)
(0.98–1.04)
(0.99–1.02)
(0.64–2.09)
(0.61–1.86)

0.89
0.91
0.86
0.37
0.86
0.57
0.33
0.63
0.82

1.08
0.55
0.84
0.55
0.28
3.31

(0.58–2.05)
(0.26–1.1)
(0.44–1.67)
(0.29–0.99)
(0.08–0.73)
(1.76–6.21)

0.82
0.1
0.59
0.05
0.019
0.0002

0.97 (0.95–0.99)

0.03

1.87 (0.92–3.9)

0.09

1 (0.98–1.03)

0.74 (0.38–1.44)
0.31 (0.08–0.89)
3.42 (1.74–6.75)

0.77

0.38
0.047
0.0004

CD, Crohn’s disease; UC, ulcerative colitis.

cardiovascular parameters with TNF-alpha antagonist use.20 Animal studies have shown deceleration of atherosclerosis with these
medications21; however, this has not translated into convincing
human studies. Moreover, there have been reports of cardiovascular events after TNF-alpha antagonist infusion.22 Therefore, the
effect of these medications on the heart remains controversial.
These medications are being increasingly used in the management of IBD patients, and their long-term effect on the cardiovascular system should be further investigated.
The authors also observed a trend toward increased
incidence of cardiovascular disorders among patients requiring
disease-related hospitalization. This is consistent with previous
studies that have shown increased cardiovascular events with
active IBD.7 Therefore, patients with severe IBD activity requiring
hospitalization are at increased risk of cardiovascular disorders.
They also observed decreased cardiovascular events in
patients treated with thiopurines, which is not consistent with their
current understanding that increased inﬂammation leads to cardiovascular disorders because thiopurines are often used in IBD
patients who do not respond to treatment with 5-aminosalicylate
medications and have frequent exacerbations. This ﬁnding could
be because of strong immunomodulatory effects of this class of
medications. Immunomodulatory medications are helpful in
delaying the progression of atherosclerosis, and there are several
medications such as angiotensin receptor antagonists and statins
with pleiotropic effects that have been shown to decrease
cardiovascular mortality. However, the effect of immunomodulating drugs on development of atherosclerosis is not well understood.23 Several immunomodulatory medications are being studied

for prevention of cardiovascular diseases. Thiopurines have been
used in IBD for decades and still form the mainstay of treatment
for many patients.24 Azathioprine has been shown to be a strong
inducer of T-cell apoptosis,25 and treatment with thiopurine is associated with a reduction of interferon g + T cells in IBD patients who
responded to treatment.26 Coronary artery disease is also mediated
by T cells, and CD4+CD28null T cells, which are characterized by
increased interferon g levels, are prominent in patients with acute
coronary syndromes.27 These ﬁndings suggest that thiopurines could
have a potentially protective effect on the cardiovascular system by
inhibiting deleterious T-cell–mediated effects on the heart.
Furthermore, although not statistically signiﬁcant, the
authors found patients with history of disease-related surgery to
have a strong trend toward lower cardiovascular disease
incidence. This effect could be because surgical resection of
inﬂamed bowel removes the nidus of inﬂammation and thereby
decreases the harmful effects of inﬂammation on the cardiovascular system. Therefore, proper selection of patients for
surgical treatment may not only spare them from intolerable
disease-related symptoms but also protect from harmful effects
of inﬂammation on the heart.
Furthermore, the decreased incidence of cardiovascular
events among thiopurine users and increased incidence among
TNF-alpha antagonist users were signiﬁcant on secondary analysis
comparing patients with only hard cardiovascular endpoints
(myocardial infarction, stroke and heart failure) and the control
group. This further lends support to the robustness of their ﬁndings.
The main drawback of this study is its retrospective
design. It is also a single tertiary center study. The cohort
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comprised of patients between the age of 30 and 74 years and
did not include younger or older patients because the Framingham risk score is applicable only in this age group. Therefore,
the results of this study do not apply to patients who are
younger or older than this cohort. Another important drawback
of this study is that the severity of IBD was measured using
surrogate markers and not evaluated directly because of the
retrospective nature of the study. Finally, the tests that were
performed and medications that were administered were part of
routine clinical care and not study interventions.

CONCLUSIONS
Increased cardiovascular disease incidence was observed in
patients treated with TNF-alpha antagonists and patients requiring
disease-related hospitalization over the follow-up period, supporting the role of inﬂammation in cardiovascular events in patients
with IBD. Paradoxically, decreased incidence of cardiovascular
disease in patients treated with thiopurines and patients who
underwent disease-related surgery was also observed.
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